Localized Tracheobronchial Amyloidosis Characteristics and Management

Introduction to Localized Amyloidosis

Localized tracheobronchial amyloidosis is considered a separate entity from systemic amyloidosis and typically does not progress to involve other organs or sites in the body 1
Localized amyloidosis results from local synthesis of amyloid protein, while systemic amyloidosis involves widespread deposition of amyloid proteins produced at distant sites 2
Tracheobronchial amyloidosis is considered an idiopathic localized disorder characterized by deposition of fibrillar proteins in the tracheobronchial tree 1
This form of amyloidosis is distinct from primary idiopathic amyloidosis or amyloid light-chain amyloidosis, which can affect multiple organs 1

The deposition of amyloid in the airway submucosa is slow and gradual, with average age at diagnosis around 55 years 1
Main symptoms include cough, wheezing (often misdiagnosed as asthma), and hemoptysis 1
Bronchoscopic visualization typically reveals a diffuse submucosal infiltrative process in the trachea and bronchi, which can appear nodular, tumor-like, or polypoid 1
Biopsy of airway lesions is diagnostic, showing characteristic Congo red staining with apple-green birefringence under polarized light 3

Treatment options include local therapy (bronchoscopic debulking and laser ablation), systemic chemotherapy, and radiation therapy 1
Recurrence of disease is common despite treatment 1
Systemic amyloidosis typically affects multiple organs simultaneously, particularly the heart and kidneys 2
AL amyloidosis (the most common systemic form) is associated with plasma cell disorders and requires systemic therapy targeting the underlying protein production 3
Systemic amyloidosis has a poorer prognosis, particularly with cardiac involvement 2